Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)
CAPS Rating:
The Company is engaged in the discovery and development of synthetic DNA and RNA-based compounds for the treatment of cancer, infectious diseases, autoimmune diseases, and asthma/allergies, and for use as vaccine adjuvants.
RSS Headlines
Fool UK
Recs
medical/biotech related picks - 4 buys / 4 sells
BUY:exel,idra,rtix,dcth
SELL:pbth,pcyc,vrtx,nbix